AnjaliTOwensMD

Adult Congenital Heart Disease, Cardiac Electrophysiology, Heart Failure & Transplantation, Interventional Cardiology

Assistant Professor, Medicine, Perelman School of Medicine

Dr. Owens is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

University of Pennsylvania Health SystemFellowship, Cardiovascular Disease, 2010 - 2011
University of Pennsylvania Health SystemFellowship, Cardiovascular Disease, 2007 - 2010
University of Pennsylvania Health SystemResidency, Internal Medicine, 2003 - 2006
Duke University School of MedicineClass of 2003, B.A.

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

HCMR - Novel Markers of Prognosis in Hypertrophic Cardiomyopathy Start of enrollment: 2014 Apr 01
Active, not recruiting
DCM Precision Medicine Study Start of enrollment: 2016 Jun 07
Active, not recruiting
Not Applicable

PubMed

2 citations
The Clinical Trajectory of NYHA Functional Class I Patients With Obstructive Hypertrophic Cardiomyopathy.
Monica Ahluwalia, Jiankang Liu, Iacopo Olivotto, Victoria Parikh, Euan A Ashley
JACC. Heart Failure. 2025-02-01
Sex-Specific Clinical and Genetic Factors Associated With Adverse Outcomes in Hypertrophic Cardiomyopathy.
Alexandra Butters, Clare Arnott, Joanna Sweeting, Brian Claggett, Anna Cuomo
Circulation. Genomic and Precision Medicine. 2025-01-24
Limited Concordance of Left Ventricular Ejection Fraction and Chamber Dimensions With Automated Assessments in Hypertrophic Cardiomyopathy: A Substudy From VALOR-HCM.
Gary Parizher, Alice Haouzi, Wael A Jaber, Anjali Owens, Kathy Wolski
Journal of the American Society of Echocardiography. 2024-12-28

Journal Articles

Applicability of US Food and Drug Administration Labeling for Dapagliflozin to Patients with Heart Failure with Reduced Ejection Fraction in US Clinical Practice
Muthiah Vaduganathan, Javed Butler, Paul A Heidenreich, Michelle M Kittleson, Anjali Tiku Owens, Pamela N Peterson, Clyde W Yancy, Gregg C Fonarow, JAMA Cardiology

Lectures

Genetic Testing in HCM: Where are We Now and Where to Do We Need to Go?
2019 ACC Scientific Session & Expo, New Orleans - 3/16/2019

Diagnosis of Hypertrophic Cardiomyopathy: What Every Cardiologist Needs to KnowFebruary 2020
Diagnosis of Hypertrophic Cardiomyopathy: What Every Cardiologist Needs to KnowFebruary 2020

Cytokinetics Presents Additional Data from SEQUOIA-HCM at the HCMS Scientific SessionsSeptember 27th, 2024
U.S. Food and Drug Administration Approves Camzyos™ (Mavacamten) for the Treatment of Adults with Symptomatic New York Heart Association Class II-III Obstructive Hypertrophic Cardiomyopathy (HCM) to Improve Functional Capacity and SymptomsApril 29th, 2022
FDA Approves Mavacamten, First Treatment for Obstructive Hypertrophic CardiomyopathyApril 29th, 2022
Join now to see all